S2k guideline for the treatment of hidradenitis suppurativa / acne inversa – Short version

Keyphrases

• Abnormal Differentiation 10%
• Abscess 10%
• Acne Inversa 100%
• Activity Measurement 10%
• Adalimumab 10%
• Apocrine Gland 10%
• Bimekizumab 10%
• Classification Performance 10%
• Clindamycin 20%
• Decision Aid 10%
• Decision Assessment 10%
• Decision Classification 10%
• Disease Pattern 10%
• Germany 10%
• Glands 10%
• Hair Follicle 20%
• Hidradenitis Suppurativa 100%
• Holistic Therapy 10%
• IHS4 20%
• Inflammation 20%
• Inflammatory Lesions 10%
• Inflammatory Nodule 10%
• Instrument Validation 10%
• Intravenous Therapy 10%
• Keratinocytes 10%
• Non-inflammatory Diseases 10%
• Noninflammatory 10%
• Point Prevalence Survey 10%
• Predilection Site 10%
• Quality of Life 10%
• Rifampicin 10%
• Secukinumab 10%
• Severity Scoring System 10%
• Skin Diseases 10%
• Surgical Procedures 10%
• Terminal Hair 10%
• Tetracycline 10%
• Therapy Method 10%
• Treatment Decisions 10%

Medicine and Dentistry

• Abscess 5%
• Adalimumab 5%
• Apocrine Gland 5%
• Bimekizumab 5%
• Clindamycin 10%
• Dermatosis 5%
• Hair Follicle 10%
• Hidradenitis Suppurativa 100%
• Inflammatory Disorder 5%
• Intravenous Drug Administration 5%
• Keratinocyte 5%
• Oral 5%
• Prevalence 5%
• Quality of Life 5%
• Recurrent Disease 5%
• Rifampicin 5%
• Scoring System 5%
• Secukinumab 5%
• Serositis 5%
• Surgical Technique 5%

Immunology and Microbiology

• Abscess 5%
• Adalimumab 5%
• Apocrine Gland 5%
• Bimekizumab 5%
• Hair Follicle 10%
• Hidradenitis Suppurativa 100%
• Inflammatory Disorder 5%
• Keratinocyte 5%
• Prevalence 5%
• Secukinumab 5%